JPRN-jRCTs031190066
Completed
Phase 2
A Phase 2 Study of atezolizumab + carboplatin + paclitaxel + bevacizumab for previously-treated patients with NSCLC harboring EGFR mutations. - NEJ043
Kikuchi Toshiaki0 sites60 target enrollmentAugust 1, 2019
Conditionson-sequamous non-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-sequamous non-small cell lung cancer
- Sponsor
- Kikuchi Toshiaki
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Stage III or IV Non\-Squamous, non\-small cell lung cancer proven by histology and/or cytology without indication of curative surgery or curative radiotherapy, 2\) Sensitizing EGFR mutations (19 deletion, L858R, G719X, S768I, L861Q, T790M), 3\) Prior therapy with EGFR\-TKIs, 4\) Measurable disease, as defined by RECIST ver 1\.1, 5\) No prior cytotoxic chemotherapy or immunotherapy, 6\) 20 years or older, 7\) ECOG PS 0 or 1, 8\) adequate hematologic and end organ function, 9\) Written informed consent form.
Exclusion Criteria
- •1\) History of interstitial lung disease or radiation pneumonitis, 2\) Symptomatic CNS metastases, CNS metastases treated with corticosteroids, leptomeningeal disease, 3\) Irradiation for primary tumor or target lesion defined by RECIST ver 1\.1, 4\) Uncontrolled heart, lung, liver, renal diseases, 5\) History of autoimmune diseases, 6\) Known hypersensitivity or allergy to paclitaxel or polyoxyethylene castor oil containing formulations, 7\) History of hemoptysis, 8\)Invasion to major vessels or heart, 9\) Treatment with systemic corticosteroid or immunosuppressant, 10\) Patients with active hepatitis B or hepatitis C or positive for HIV test, 11\) Women who are pregnant, lactating, or intending to become pregnant during the study, 12\) Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, 13\) Malignancies other than NSCLC within 5 years, 14\) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, 15\) Plan for major surgical procedure during the course of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
A phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung canceron-squamous non-small cell lung cancerJPRN-jRCTs041200032Itani Hidetoshi60
Not yet recruiting
Phase 2
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”2024-519514-31-00Consorzio Oncotech104
Active, not recruiting
Phase 2
Atezolizumab Plus CArboplatin Plus Nab-paclitaxelMetastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene MutationNCT05266937Consorzio Oncotech49
Active, not recruiting
Phase 2
OGIK2002(RESTART)Treatment-naive advanced non-squamous non-small cell lung cancerNSCLC, advanced, renal dysfunctionD002289JPRN-jRCTs071200102Okamoto Isamu25
Completed
Phase 2
AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trialNL-OMON48948ederlands Kanker Instituut40